Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30664339 | 1.00 | CNR2 (0.52) | CNR2PDE10AATRATRIPWNT3A | |
| SCHEMBL23862435 | 0.89 | CNR2 (0.48) | CNR2PDE10AATRATRIPWNT3A | |
| SCHEMBL30664237 | 0.83 | JMJD6 (0.43) | PDE10AATRATRIPKCNH2 | |
| SCHEMBL20122899 | 0.83 | JMJD6 (0.43) | PDE10AATRATRIPKCNH2 | |
| SCHEMBL20122933 | 0.83 | CAMKK2 (0.43) | — | |
| SCHEMBL30664304 | 0.82 | DYRK1A (0.42) | PDE10A | |
| SCHEMBL20122852 | 0.82 | DYRK1A (0.42) | PDE10A | |
| SCHEMBL20122737 | 0.81 | RET (0.40) | CNR2RET | |
| SCHEMBL20123008 | 0.80 | PDE4B (0.46) | CNR2 | |
| SCHEMBL30664272 | 0.80 | PDE4B (0.46) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| EP-3792262-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2021-03-17 | — | — | EP | disclosed |
| EP-3535263-B1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2020-09-30 | — | — | EP | disclosed |
| EP-3318563-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2018-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | CNR2 120/4885PDE10A 415/4885ATR 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.